Increased von Willebrand Factor in Acute Stroke Patients With Atrial Fibrillation

2006 ◽  
Vol 15 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Mika Sato ◽  
Akifumi Suzuki ◽  
Ken Nagata ◽  
Shinichiro Uchiyama
Keyword(s):  
Atrial Fibrillation ◽  
Acute Stroke ◽  
Von Willebrand Factor ◽  
Stroke Patients ◽  
Von Willebrand ◽  
Willebrand Factor

Levels of von Willebrand factor and ADAMTS13 determine clinical outcome after cardioversion for atrial fibrillation

2011 ◽  
Vol 105 (03) ◽  
pp. 435-443 ◽  
Author(s):  
Veronika Bruno ◽  
Rudolf Jarai ◽  
Susanne Gruber ◽  
Thomas Höchtl ◽  
Ivan Brozovic ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Von Willebrand Factor ◽  
Platelet Adhesion ◽  
Independent Predictor ◽  
Thrombus Formation ◽  
Critical Role ◽  
Inverse Correlation ◽  
Von Willebrand ◽  
Rhythm Stability ◽  
Willebrand Factor

SummaryVon Willebrand factor (vWF) plays an essential role in platelet adhesion and thrombus formation. Patients with atrial fibrillation (AF) exhibit higher plasma vWF and lower ADAMTS13 antigen levels compared to controls. Little is known about vWF and ADAMTS13 in AF patients treated with cardioversion (CV). Thus we investigated the alterations of plasma vWF and ADAMTS13 after CV and evaluated the predictive value of these parameters for recurrence of AF. In this observational study we determined plasma levels of vWF and ADAMTS13 in 77 patients before and immediately after CV, as well as 24 hours (h) and six weeks thereafter, by means of commercially available assays. The vWF/ ADAMTS13-ratio was significantly elevated immediately after CV (p=0.02) and 24 h after CV (p=0.002) as compared to baseline levels. ADAMTS13, 24 h after CV, exhibited a significant association with recurrence of AF (HR: 0.97; p=0.037). Accordingly, tertiles of ADAMTS13 showed a stepwise inverse correlation with the risk of recurrent AF (HR: 0.50; p=0.009). After adjustment for confounders, ADAMTS13 remained significant as an independent predictor of recurrent AF (HR: 0.61; p=0.047). Similarly, the vWF/ADAMTS13-ratio, 24 h after CV, was associated with rhythm stability and remained an independent predictor of recurrent AF (HR: 1.88; p=0.028). The regulation of vWF and its cleaving protease ADAMTS13 after CV might play a critical role in producing a pro-thrombotic milieu immediately after CV for AF. Since ADAMTS13 plasma concentration and the vWF/ADAMTS13-ratio are independently associated with rhythm stability, these indexes might be used for prediction of recurrence of AF.

Abstract 2641: Plasma Von Willebrand Factor and ADAMTS13 Concentrations in Atrial Fibrillation

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Takashi Uemura ◽  
Koichi Kaikita ◽  
Hiroshige Yamabe ◽  
Masakazu Matsukawa ◽  
Kenji Soejima ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Von Willebrand Factor ◽  
Left Atrial ◽  
Thrombus Formation ◽  
Significant Negative Correlation ◽  
Platelet Surface ◽  
Control Subjects ◽  
Number Of Patients ◽  
Von Willebrand ◽  
Willebrand Factor

Background : Von Willebrand factor (VWF) is released from damaged endothelium, and has a role in platelet aggregation through a receptor on the platelet surface. A metalloprotease that cleaves VWF multimers has been identified, namely, ADAMTS13. We recently reported that the serial changes in plasma VWF and ADAMTS13 antigen levels in patients with acute myocardial infarction (AMI), and that the VWF/ADAMTS13 ratio was a useful prognostic indicator of long-term thrombotic events after AMI. Although previous studies have shown raised plasma VWF in patients with atrial fibrillation (AF), little is known about the role of ADAMTS13 in the pathogenesis of AF. In the present study, we examined the relation between VWF and ADAMTS13 in AF patients. Methods and Results : We measured the plasma VWF and ADAMTS13 antigen levels by ELISA in 45 AF patients and 49 control subjects, and also performed echocardiography to examine the relations between these markers and left atrial or ventricular functions. The plasma VWF antigen levels were significantly higher in AF patients compared with controls (2017±749 vs. 1504±497 mU/ml, P=0.0002). In contrast, the plasma ADAMTS13 antigen levels were significantly lower in AF patients compared with controls (825±181 vs. 911±193 mU/ml, P=0.03). The VWF/ADAMTS13 ratio was significantly higher in AF patients compared with controls (2.59±1.20 vs. 1.75±0.76, P<0.0001). The number of patients who received aspirin and warfarin was significantly higher in AF group than control subjects, however, those medical therapy did not affect the VWF and ADAMTS13 antigen levels. There was significant positive correlation between VWF antigen levels and the left atrial dimension (n=128, r=0.228, P=0.0095). Furthermore, there was significant negative correlation between VWF antigen levels and the left atrial appendage peak flow velocity measured by transesophageal echocardiography (n=23, r=-0.611, p=0.0015). Conclusions : These findings suggest that the balance between VWF and ADAMTS13 levels may play an important role in the intra-atrial thrombus formation in AF patients. The present results would open a new therapeutic target for prevention of thromboembolic complications in AF.

scholarly journals Relationship of Von Willebrand Factor with carotid artery and aortic arch calcification in ischemic stroke patients

2013 ◽  
Vol 230 (2) ◽  
pp. 210-215 ◽  
Author(s):  
Michelle A.H. Sonneveld ◽  
Anouk C. van Dijk ◽  
Evita G. van den Herik ◽  
Janine E. van Loon ◽  
Lonneke M.L. de Lau ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Carotid Artery ◽  
Aortic Arch ◽  
Von Willebrand Factor ◽  
Stroke Patients ◽  
Von Willebrand ◽  
Relationship Of ◽  
Willebrand Factor ◽  
Aortic Arch Calcification

Prognostic value of von Willebrand factor for patients with atrial fibrillation: a meta-analysis of prospective cohort studies

2019 ◽  
Vol 96 (1135) ◽  
pp. 267-276 ◽  
Author(s):  
Yuan-Zheng Ye ◽  
Ya-Fei Chang ◽  
Bao-Zhu Wang ◽  
Yi-Tong Ma ◽  
Xiang Ma
Keyword(s):  
Atrial Fibrillation ◽  
Cohort Studies ◽  
Von Willebrand Factor ◽  
Prospective Cohort ◽  
Meta Analysis ◽  
Cardiovascular Death ◽  
Cochrane Library ◽  
Prospective Cohort Studies ◽  
Von Willebrand ◽  
Willebrand Factor

BackgroundIt is unknown whether an abnormal level of von Willebrand factor (vWF) is correlated with the prognosis of patients with atrial fibrillation (AF) and current findings are controversial. This meta-analysis aimed to evaluate the association between vWF levels and the clinical prognosis of patients with AF.MethodsWe searched prospective cohort studies on PubMed, Embase, Web of Science, Cochrane Library and WanFang databases for vWF and adverse events of AF from inception of the databases to July 2019. The risk ratios of all-cause death, cardiovascular death, major adverse cardiac events (MACE), stroke and bleeding prognosis in patients with AF were analysed using a fixed-effects model or random-effects model, and all included studies were evaluated with heterogeneity and publication bias analysis.ResultsTwelve studies which included 7449 patients with AF were used in the meta-analysis. The average age was 71.3 years and the average follow-up time was 3.38 years. The analysis found that high vWF levels were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death (RR 1.91; 95% CI 1.20 to 3.03, p=0.00600), MACE (RR 1.83; 95% CI 1.28 to 2.62, p=0.00090), stroke (RR 1.69; 95% CI 1.08 to 2.64, p=0.02000) and bleeding (RR 2.01; 95% CI 1.65 to 2.45, p<0.00001) in patients with AF.ConclusionsvWF is a risk factor for poor prognosis of AF, and patients with higher vWF levels have a higher risk of all-cause death, cardiovascular death, MACE, stroke and bleeding.

scholarly journals Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer levels in acute-onset nonrheumatic atrial fibrillation

2003 ◽  
Vol 41 (6) ◽  
pp. 130
Author(s):  
Francisco Marin ◽  
Vanessa Roldán ◽  
Vicente Climent ◽  
Alicia Ibáñez ◽  
Amaya García ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Von Willebrand Factor ◽  
Acute Onset ◽  
Soluble Thrombomodulin ◽  
Von Willebrand ◽  
Willebrand Factor ◽  
D Dimer
Sign in / Sign up

Export Citation Format

Share Document